Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population

Introduction Due to the vaccine’s short supply and the efficacy of a single dose of the ChAdOx1 (AZD1222) vaccine, many governments delayed the interval between prime and boost dose from 4 to 8–12 weeks. However, the waning of immune response in this period is a concern. This study evaluated the dur...

Full description

Bibliographic Details
Main Authors: Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Harnphadungkit Monprach, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
chadox1
azd1222
covid-19 vaccine
single-dose vaccine
immunogenicity
safety
Online Access:http://dx.doi.org/10.1080/21645515.2022.2035573

Internet

http://dx.doi.org/10.1080/21645515.2022.2035573

Similar Items